- Home
- CRIS vs ESLA Comparison
CRIS vs ESLA Comparison
Compare CRIS & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- ESLA
- Stock Information
- Founded
- CRIS 2000
- ESLA 2021
- Country
- CRIS United States
- ESLA United States
- Employees
- CRIS N/A
- ESLA N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRIS Health Care
- ESLA Health Care
- Exchange
- CRIS Nasdaq
- ESLA Nasdaq
- Market Cap
- CRIS 32.8M
- ESLA 37.3M
- IPO Year
- CRIS 2000
- ESLA N/A
- Fundamental
- Price
- CRIS $1.48
- ESLA $0.79
- Analyst Decision
- CRIS Strong Buy
- ESLA Strong Buy
- Analyst Count
- CRIS 3
- ESLA 1
- Target Price
- CRIS $21.00
- ESLA $16.00
- AVG Volume (30 Days)
- CRIS 51.0K
- ESLA 39.5K
- Earning Date
- CRIS 03-31-2025
- ESLA 05-14-2025
- Dividend Yield
- CRIS N/A
- ESLA N/A
- EPS Growth
- CRIS N/A
- ESLA N/A
- EPS
- CRIS N/A
- ESLA N/A
- Revenue
- CRIS $10,908,000.00
- ESLA N/A
- Revenue This Year
- CRIS N/A
- ESLA $402.53
- Revenue Next Year
- CRIS $27.88
- ESLA N/A
- P/E Ratio
- CRIS N/A
- ESLA N/A
- Revenue Growth
- CRIS 8.83
- ESLA N/A
- 52 Week Low
- CRIS $1.42
- ESLA $0.63
- 52 Week High
- CRIS $17.49
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- CRIS 18.52
- ESLA 41.36
- Support Level
- CRIS $2.57
- ESLA $0.87
- Resistance Level
- CRIS $2.62
- ESLA $0.98
- Average True Range (ATR)
- CRIS 0.26
- ESLA 0.09
- MACD
- CRIS -0.07
- ESLA 0.00
- Stochastic Oscillator
- CRIS 10.88
- ESLA 32.04
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.